Product Description
Desirudin is used to prevent deep venous thrombosis, a condition in which harmful blood clots form in the blood vessels of the legs. These blood clots can travel to the lungs and can become lodged in the blood vessels of the lungs, causing a condition called pulmonary embolism. This medicine is used for several days after hip replacement surgery, while you are unable to walk. It is during this time that blood clots are most likely to form. (Sourced from: https://www.mayoclinic.org/drugs-supplements/desirudin-subcutaneous-route/description/drg-20074071)
Mechanisms of Action: Thrombin Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | European Medicines Agency | Germany | Greece | Hungary | Ireland | New Zealand | Portugal | Sweden
Approved Indications: None
Known Adverse Events: None
Company: Canyon
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Thrombosis
Phase 3: Venous Thrombosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| DESIR-ABLE | P4 |
Completed |
Thrombosis |
2011-06-01 |
2019-03-18 |
Treatments |
|
| NCT00329433 | P3 |
Completed |
Venous Thrombosis |
2008-10-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/13/2019 |
News Article |
Physicians, Patients Overwhelmingly Support FDA Distinct Biologic Naming Plan, Suffixes for New Products |